GSK's Nucala (mepolizumab) Receives the US FDA's Approval for the Treatment of Chronic Rhinosinusitis with Nasal Polyps
Shots:
- The approval is based on data from the SYNAPSE study evaluating mepolizumab vs PBO in ~400 patients with CRSwNP who had a history of prior surgery & need further surgery due to severe symptoms & increased size of polyps
- The results showed a 57% reduction in the size of nasal polyps & nasal obstruction in patients who had surgery whereas the proportion of patients requiring systemic corticosteroid use through 52 wks. of the treatment period was lower who received the therapy
- Mepolizumab is the 1st anti-IL-5 biologic to be approved for CRSwNP & marks the 4th indication for eosinophil-driven diseases in the US
Ref: Businesswire | Image: GSK
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com